IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
19.57
+0.15 (0.77%)
At close: May 28, 2025, 4:00 PM
19.56
-0.01 (-0.05%)
After-hours: May 28, 2025, 4:00 PM EDT
IDEAYA Biosciences Analyst Ratings
Total Analysts
12
Consensus Rating
Strong Buy
Price Target
$54.27
Upside
+177.31%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $63 → $66 | Buy | Maintains | $63 → $66 | +237.25% | May 22, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $50 | Buy | Reiterates | $50 | +155.49% | Feb 14, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $61 | Buy | Reiterates | $61 | +211.70% | Jan 15, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 17, 2024 |
| Wedbush | Wedbush | Buy Reiterates $52 | Buy | Reiterates | $52 | +165.71% | Dec 17, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $51 | Buy | Initiates | $51 | +160.60% | Nov 18, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $41 → $27 | Buy → Hold | Downgrades | $41 → $27 | +37.97% | Nov 5, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $53 | Buy | Reiterates | $53 | +170.82% | Oct 29, 2024 |
| UBS | UBS | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +155.49% | Oct 24, 2024 |
| Wedbush | Wedbush | Buy Maintains $54 → $52 | Buy | Maintains | $54 → $52 | +165.71% | Sep 24, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $61 | Buy | Reiterates | $61 | +211.70% | Sep 24, 2024 |
| Stifel | Stifel | Strong Buy Maintains $63 → $68 | Strong Buy | Maintains | $63 → $68 | +247.47% | Sep 10, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $60 → $58 | Strong Buy | Maintains | $60 → $58 | +196.37% | Aug 27, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $69 → $66 | Buy | Maintains | $69 → $66 | +237.25% | Aug 8, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $61 | Buy | Reiterates | $61 | +211.70% | Aug 7, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.